On May 28, 2026 Molecular Targeting Technologies, Inc. (MTTI) reported the clinical findings of the Next-Generation PRRT, ¹⁷⁷Lu-DOTA-EB-TATE to treat GEP-NET Patients. The Phase 1 dose-escalation and dosimetry study will be presented at the 2026 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, taking place May 29–June 3, 2026, in Los Angeles, California.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Neuroendocrine tumors (NETs) are often detected late, limiting curative treatments and requiring systemic therapies like Peptide Receptor Radionuclide Therapy (PRRT). While 177Lu-DOTATATE has demonstrated efficacy, its rapid clearance limits tumor radiation delivery and may increase renal toxicity risk.

"Our Clinical findings suggest that EBTATE may achieve meaningful clinical responses after only two treatment cycles while delivering approximately 12.5% of the cumulative radioactivity required for standard PRRT," said Chris Pak, Chairman and Chief Executive Officer of MTTI. "If validated in larger studies, EBTATE could represent a transformative advance in radiopharmaceutical therapy, shortening treatment duration, reducing radiation exposure, and enabling physicians to evaluate efficacy much earlier than is possible today."

"EBTATE achieved substantially higher tumor uptake and prolonged retention than conventional ¹⁷⁷Lu-DOTATATE while maintaining a favorable safety profile, with no kidney toxicity observed for one year follow-up," said Lisa Bodei, MD, PhD, a nuclear medicine physician at Memorial Sloan Kettering Cancer Center. "The ability to deliver greater tumor radiation with significantly less administered radioactivity positions EBTATE as a potentially transformative PRRT. These data also support the possibility of a streamlined two-cycle regimen, enabling earlier evaluation of treatment efficacy."

The presentation entitled, "Next-Generation PRRT" by Dr. Bodei (poster # 261874). The poster has also been selected for a 10-minute oral presentation during the 2026 Patient Education Day NETS Program Schedule (View Source), on 5/31/26 during the SNMMI meeting.

MTTI will present its proprietary Evans Blue (EB) albumin-binding technology platform at Booth #1758 during the SNMMI Annual Meeting, featuring clinical data from 81 GEP-NET patients and compelling preclinical results.

MTTI’s EB technology enhances tumor targeting through reversible albumin binding, delivering up to 26-fold greater tumor retention in preclinical models and approximately eight-fold higher tumor uptake in patients compared with conventional DOTA-TATE. These findings position the platform as a potentially transformative approach for next-generation radiopharmaceuticals, with the potential to improve efficacy, expand therapeutic opportunities, and create significant strategic value.

(Press release, Molecular Targeting Technologies, MAY 28, 2026, View Source [SID1234666175])

On May 28, 2026 Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, reported enrollment of the first patients in SIgnatera-Guided iNterventionAL (SIGNAL)-ER 101, a prospective, single-arm, multi-center study evaluating Signatera MRD-guided de-escalation in early-stage breast cancer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The current standard of care recommends two or three years of an adjuvant CDK4/6 inhibitor in combination with endocrine therapy for patients with intermediate-risk, hormone receptor (HR) positive, HER2 negative, early stage breast cancer. This is despite the fact that only ~3% of eligible patients derive benefit, over 60% of patients experience serious adverse events,1-2 and the U.S. retail costs can be over $400,000 for a full course of treatment. Meanwhile, data presented at SABCS 2025 from the PALLAS trial show that HR+ breast cancer patients who tested MRD-negative with Signatera had excellent long-term outcomes, with >95% distant recurrence-free interval at 5 years. This suggests that MRD-negative patients can safely defer CDK4/6 inhibition with no impact to clinical outcomes, with the provision that it be added if and when MRD is detected on serial testing using a TOMR (Treatment on MRD) approach.

SIGNAL-ER 101 plans to enroll approximately 725 patients across 50 sites in the United States. Patients who test MRD-positive will receive endocrine therapy plus CDK4/6 inhibitors, while those who test MRD-negative (the vast majority of patients) will receive endocrine therapy alone with quarterly Signatera monitoring. Patients who become MRD-positive during surveillance will be eligible to initiate CDK4/6 inhibition at that time, consistent with the TOMR approach.

"Many women with this type and stage of breast cancer are overtreated, which can have a profound impact on their quality of life," said Minetta Liu, M.D., chief medical officer, oncology and early cancer detection at Natera. "SIGNAL-ER 101 is a key part of our evidence generation roadmap, to support Signatera-guided treatment optimization without compromising the survival benefit from CDK4/6 inhibitors. This approach also allows patients to get the most effective treatment when Signatera shows it is necessary."

SIGNAL-ER 101 is the first in a series of innovative Natera-sponsored SIGNAL trials across multiple cancer types, designed to demonstrate that MRD-negative patients may be able to delay or defer treatment. There are many instances of overtreatment in cancer. This concept has already been studied in the IMvigor011 trial where MRD-negative patients with muscle-invasive bladder cancer achieved 97% overall survival at 2 years without any adjuvant therapy, and in the GALAXY and CALGB/SWOG 80702 trials, where MRD-negative patients with colorectal cancer saw no clinical benefit from adjuvant chemotherapy and celecoxib, respectively.

(Press release, Natera, MAY 28, 2026, View Source [SID1234666174])

On May 28, 2026 Daiichi Sankyo (TSE: 4568) reported it will present new clinical research across its oncology portfolio with more than 25 abstracts in multiple cancers at the 2026 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting (#ASCO26).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Data at ASCO (Free ASCO Whitepaper) will highlight the company’s progress toward advancing new standards of care for patients with cancer, including new analyses from five landmark trials in breast and gastric cancer, including the DESTINY-Breast05 (#516), DESTINY-Breast06 (#1063), DESTINY-Breast09 (#1021) and DESTINY-Gastric04 (#4111) phase 3 trials of Enhertu (trastuzumab deruxtecan), and the TROPION-Breast02 (#1002) phase 3 trial of Datroway (datopotamab deruxtecan). Additional results from earlier phase trials as well as trials-in-progress across new medicines being developed through the company’s breakthrough generating technology (BGT), a platform-based drug discovery model designed to deliver innovative medicines to patients faster, will be highlighted.

Data from DESTINY-Breast05 formed the basis of one of two new Enhertu indications recently approved in the U.S. for certain patients with early-stage HER2 positive breast cancer and data from DESTINY-Gastric04 was included as part of a label update to expand the use of Enhertu in Japan and China to include the second-line treatment of patients with HER2 positive metastatic gastric cancer. Additionally, results from TROPION-Breast02 formed the basis of the recent U.S. approval of Datroway in patients with metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy, the first antibody drug conjugate (ADC) to be approved in this setting of TNBC.

"The approvals received just prior to ASCO (Free ASCO Whitepaper) for Enhertu and Datroway, two of our leading DXd antibody drug conjugates, together with the strong science being showcased across our pipeline, highlight the momentum of our oncology portfolio," said John Tsai, MD, Global Head, R&D, Daiichi Sankyo. "Daiichi Sankyo is committed to creating new standards of care for patients with cancer and continues to leverage its scientific and technological expertise to advance innovation."

Additional Enhertu Data Spans Broad Range of HER2 Expressing Cancers
Additional research updates across several additional HER2 expressing cancers include oral and poster sessions highlighting the preliminary safety run-in results from the DESTINY-Ovarian01 (#5554) phase 3 trial evaluating Enhertu in combination with bevacizumab compared to bevacizumab monotherapy as a first-line maintenance therapy in patients with HER2 expressing ovarian cancer; the primary analysis from part 1 of the DESTINY-PanTumor03 (#3026) phase 2 trial evaluating Enhertu in pretreated patients in China with HER2 positive (IHC 3+) solid tumors (excluding breast and gastric cancer); and, findings from the MYTHOS (#6011) phase 2 trial evaluating Enhertu in patients with HER2-low recurrent or metastatic salivary gland cancer.

Additional breast and gastric cancer data for Enhertu include an oral presentation from one arm of the DESTINY-Breast07 (#1012) phase 1b/2 trial evaluating Enhertu in combination with durvalumab as a first-line treatment in patients with HER2 positive metastatic breast cancer and a poster presentation highlighting a safety analysis from the DESTINY-Gastric03 (#4022) phase 1b/2 trial evaluating Enhertu in combination with chemotherapy and immunotherapy as a first-line treatment in patients with HER2 expressing metastatic gastric cancer, gastroesophageal junction (GEJ) adenocarcinoma or esophageal adenocarcinoma.

Results from cohort two of the EPOC2203 (#4024) phase 1b/2 trial evaluating Enhertu in combination with nivolumab and capecitabine and oxaliplatin in patients with HER2 low gastroesophageal adenocarcinoma and an exploratory analysis of translational data from the EPOC2003 (#3129) phase 2 trial evaluating neoadjuvant chemotherapy in combination with Enhertu in patients with HER2 positive gastric cancer will be highlighted as poster presentations.

New Data and Trials-in-Progress Presentations Across Oncology Portfolio
Poster presentations will include a trial-in-progress update of REJOICE-Ovarian01 (TPS5637) for the phase 3 part of a phase 2/3 trial evaluating raludotatug deruxtecan (R-DXd) compared to treatment of physician’s choice in patients with platinum-resistant ovarian cancer. Two additional poster presentations will highlight an exposure-response analysis (#5570) and a population pharmacokinetic analysis (#5571) of data from both the REJOICE-Ovarian01 phase 2/3 trial and the phase 1 trial evaluating raludotatug deruxtecan in patients with advanced ovarian cancer or renal cell carcinoma.

An oral presentation will highlight results from a phase 1/2 trial (#6504) of Vanflyta (quizartinib) plus decitabine and venetoclax in patients with newly diagnosed or relapsed/refractory FLT3-ITD acute myeloid leukemia.

Trials-in-progress poster presentations across the DXd ADC portfolio include the TROPION-Urothelial03 (TPS4642) phase 2/3 trial evaluating Datroway and platinum chemotherapy compared to gemcitabine plus platinum chemotherapy in patients with locally advanced or metastatic urothelial carcinoma; the HERTHENA-Breast04 (TPS1149) phase 3 trial evaluating patritumab deruxtecan (HER3-DXd) compared to treatment of physician’s choice in patients with HR positive, HER2 negative unresectable locally advanced or metastatic breast cancer; and the DESTINY-PanTumor04 (TPS11202) hybrid observational trial evaluating Enhertu in patients with HER2 positive (IHC 3+) solid tumors.

Trials-in-Progress Presentations Highlight Breakthrough Generating Technology Focus
Daiichi Sankyo is leveraging its strength in science and technology to create new medicines for patients with cancer through its BGT approach which is designed to deliver innovative medicines to patients faster and with a higher probability of success. Trials-in-progress poster presentations featuring three potential new medicines include DS3610 (TPS3159), a STING (stimulator of interferon genes) ADC, in patients with advanced or metastatic solid tumors; DS5361 (TPS2680), a small-molecule, nonsense-mediated mRNA decay inhibitor, in patients with advanced or metastatic solid tumors; and, DS9051 (TPS3179), a novel targeted protein degradation molecule, in patients with advanced or metastatic adrenocortical carcinoma or metastatic castration-resistant prostate cancer.

Overview of clinical data and trials-in-progress from oncology pipeline of Daiichi Sankyo include:

Presentation Title

Author

Abstract

Presentation (CDT)

Breast

A DESTINY-Breast09 analysis of treatment duration and clinical outcomes by best response to trastuzumab deruxtecan (T-DXd) + pertuzumab

Y. Park

1021

Rapid Oral Presentation
Sunday, May 31
11:30 am – 1:00 pm

Secondary safety analysis of trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in DESTINY-Breast05: clinical and demographic risk factors of interstitial lung disease and radiation pneumonitis

M. Untch

516

Rapid Oral Presentation
Monday, June 1
9:45 – 11:15 am

Neoadjuvant rilvegostomig (R) + trastuzumab deruxtecan (T-DXd) in high-risk HER2-negative breast cancer: Results from the I-SPY 2.2 trial

C. O’Sullivan

LBA514

Rapid Oral Presentation
Monday, June 1
9:45 – 11:15 am

Trastuzumab deruxtecan (T-DXd) + durvalumab in patients with previously untreated HER2 positive unresectable/metastatic breast cancer (mBC): final analysis from DESTINY-Breast07

S. Loi

1012

Oral Presentation
Sunday, May 31
8:30 – 10:00 am

First-line datopotamab deruxtecan (Dato-DXd) vs chemotherapy in patients with locally recurrent inoperable or metastatic triple negative breast cancer for whom immunotherapy was not an option: additional efficacy endpoints from the TROPION-Breast02 study

D. Cescon

1002

Oral Presentation
Tuesday, June 2
9:45 am – 12:45 pm

Impact of adherence to interstitial lung disease (ILD)/pneumonitis toxicity management guidelines on ILD/pneumonitis outcomes: a retrospective analysis of patients treated with trastuzumab deruxtecan (T-DXd) in DESTINY-Breast06

C. Mateo

1063

Poster Session
Monday, June 1
1:30 – 4:30 pm

HERTHENA-Breast04: a phase 3, randomized, open-label study evaluating the efficacy and safety of patritumab deruxtecan (HER3-DXd) versus treatment of physician’s choice in hormone receptor positive (HR +)/HER2-) unresectable locally advanced or metastatic breast cancer

B. Pistilli

TPS1149

Poster Session
Monday, June 1
1:30 – 4:30 pm

Identifying patients with human epidermal growth factor receptor 2 (HER2) low and ultralow breast cancer: use of digital, artificial intelligence-based computational algorithms to assist HER2 scoring by pathologists

S. Krishnamurthy

1022

Poster Session
Monday, June 1
1:30 – 4:30 pm

Gastric

Additional health-related quality of life analysis from DESTINY-Gastric04, a randomized phase 3 study of trastuzumab deruxtecan (T-DXd) vs ramucirumab + paclitaxel in patients with HER2 positive unresectable/metastatic gastric cancer/gastroesophageal junction adenocarcinoma

K. Shitara

4111

Poster Session
Saturday, May 30
9:00 am – 12:00 pm

First-line trastuzumab deruxtecan (T-DXd)-based regimens in advanced HER2 expressing gastric cancer, gastroesophageal junction adenocarcinoma, or esophageal adenocarcinoma: safety results from DESTINY-Gastric03 Part 2 arms D and F, and Part 4

Y. Janjigian

4022

Poster Session
Saturday, May 30
9:00 am – 12:00 pm

An open-label phase 1b/2 study of trastuzumab deruxtecan combined with nivolumab and CAPOX in patients with HER2 low gastroesophageal adenocarcinoma (EPOC2203)

Y. Aoki

4024

Poster Session
Saturday, May 30
9:00 am – 12:00 pm

Tumor and immune microenvironment remodeling with neoadjuvant trastuzumab deruxtecan in HER2 positive gastric cancer: exploratory analyses from the phase 2 EPOC2003 study

A. Kawazoe

3129

Poster Session
Saturday, May 30
1:30 – 4:30 pm

Ovarian

Trastuzumab deruxtecan (T-DXd) + bevacizumab (BEV) as first-line (1L) maintenance therapy in patients with HER2 expressing ovarian cancer: results from the DESTINY-Ovarian01 safety run-in

A. Gonzalez Martin

5554

Poster Session
Monday, June 1
9:00 am – 12:00 pm

REJOICE-Ovarian01: phase 3 part of a phase 2/3 study evaluating raludotatug deruxtecan (R-DXd) versus treatment of physician’s choice in patients with platinum-resistant ovarian cancer

D. Richardson

TPS5637

Poster Session
Monday, June 1
9:00 am – 12:00 pm

Exposure-response analyses of efficacy and safety with raludotatug deruxtecan (R-DXd), a CDH6-directed ADC, to inform dose selection for phase 3 development in platinum-resistant ovarian cancer

F. Hurtado

5570

Poster Session
Monday, June 1
9:00 am – 12:00 pm

Population pharmacokinetic analysis of raludotatug deruxtecan (R-DXd), a CDH6-directed ADC, in patients with advanced ovarian cancer or renal cell carcinoma

F. Hurtado

5571

Poster Session
Monday, June 1
9:00 am – 12:00 pm

Urothelial

TROPION-Urothelial03: a phase 2/3 study of datopotamab deruxtecan (Dato-DXd) + platinum chemotherapy vs gemcitabine + platinum chemotherapy in participants with locally advanced or metastatic urothelial carcinoma with progression on or after enfortumab vedotin + pembrolizumab

M. Galsky

TPS4642

Poster Session
Sunday, May 31
9:00 am – 12:00 pm

Salivary

Trastuzumab deruxtecan in patients with HER2 low recurrent/metastatic salivary gland carcinoma: results from the phase 2 MYTHOS trial

I. Kinoshita

6011

Oral Presentation
Monday, June 1
8:00 – 9:30 am

AML

Quizartinib in combination with decitabine and venetoclax for newly diagnosed and relapsed/refractory FLT3 mutated acute myeloid leukemia

M. Yilmaz

6504

Oral Presentation
Tuesday, June 2
9:45 am – 12:45 pm

Pan Tumor

Trastuzumab deruxtecan (T-DXd) for pretreated patients in China with HER2 IHC 3+ solid tumors: DESTINY-PanTumor03 Part 1 primary analysis

Y. Zhang

3026

Poster Session
Saturday, May 30
1:30 – 4:30 pm

A pragmatic, hybrid observational study evaluating the effectiveness of trastuzumab deruxtecan (T-DXd) in patients with HER2 IHC3+ solid tumors: DESTINY-PanTumor04

B. Monk

TPS11202

Poster Session
Monday, June 1
9:00 am – 12:00 pm

HER2 independent antitumor and pharmacodynamic responses to trastuzumab deruxtecan in patients with advanced solid tumors

S. Shin

3031

Poster Session
Saturday, May 30
1:30 – 4:30 pm

Topoisomerase 1 and DNA damage: pharmacodynamic responses and mechanism of trastuzumab deruxtecan in HER2-expressing advanced solid tumors

D. Wilsker

3092

Poster Session
Saturday, May 30
1:30 – 4:30 pm

BGT

A phase 1, first-in-human study of DS3610, a stimulator of interferon genes (STING) agonist ADC, in patients with advanced/metastatic solid tumors

S. Koganemaru

TPS3159

Poster Session
Saturday, May 30
1:30 – 4:30 pm

A phase 1, first-in-human study of DS5361, a small-molecule, nonsense-mediated mRNA decay inhibitor, in patients with advanced/metastatic solid tumors (Parts 1 and 2)

S. Sen

TPS2680

Poster Session
Saturday, May 30
1:30 – 4:30 pm

A phase 1, first-in-human study of DS9051, a novel targeted protein degradation molecule, in patients with advanced/metastatic adrenocortical carcinoma or metastatic castration-resistant prostate cancer

M. Patel

TPS3179

Poster Session
Saturday, May 30
1:30 – 4:30 pm

(Press release, Daiichi Sankyo, MAY 28, 2026, https://www.businesswire.com/news/home/20260528097415/en/Daiichi-Sankyo-Showcases-Progress-Across-Industry-Leading-Oncology-Portfolio-with-Latest-Research-Updates-at-ASCO [SID1234666173])

On May 28, 2026 Onc.AI, a digital health company developing computational biomarkers and decision-support products in oncology using Deep Learning imaging AI, reported positive external validation results for Onclara IO, an imaging-based AI biomarker that stratifies survival outcomes in patients with PD-L1-High, mutation negative metastatic non-small cell lung cancer (mNSCLC) receiving first-line immune checkpoint inhibitor (ICI) monotherapy. The findings will be presented at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) 2026 Annual Meeting in Chicago. In an external blinded validation conducted on a Flatiron Health longitudinal imaging dataset, Onclara IO derived from a single pretreatment CT scan, the patients most likely to benefit from ICI monotherapy.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In the retrospective validation cohort of 205 patients with PD-L1-High mNSCLC without actionable mutations, patients classified as Onclara IO High had a median overall survival of 484 days, compared to 155 days for Onclara IO Low patients. "These results position Onclara IO as a noninvasive imaging biomarker that complements PD-L1 testing, with the potential to inform first-line treatment selection and risk-adapted strategies in this population," said Ravi Parikh, MD, first author on this work and Medical Director of the Winship Data and Technology Applications Shared Resource at Winship Cancer Institute, Emory University.

"As longstanding partners of Onc.AI, we are pleased to see Flatiron’s high-quality, real-world data support the independent validation of Onclara IO in patients with PD-L1-high metastatic non-small cell lung cancer. These findings reinforce the value of combining curated real-world data with imaging AI to advance more precise, biomarker-informed treatment decisions, and we look forward to continuing this collaboration as Onc.AI achieves additional milestones together," said Jacqueline Law, Ph.D., VP, Scientific Engagement and Applied Research at Flatiron Health.

Onclara IO is not FDA cleared and is not available for commercial use. Onc.AI expects to submit Onclara IO for clearance as a software-as-medical-device in 2027.

(Press release, Onc AI, MAY 28, 2026, View Source [SID1234666172])

On May 28, 2026 Ontada, a McKesson business dedicated to real-world oncology data and insights, will present a real-world observational research study in an oral presentation at the American Society of Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting examining GLP-1 receptor agonist (RA) utilization and overall survival outcomes among patients treated in U.S. community oncology practices.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The study, titled, "GLP 1 receptor agonist utilization and survival outcomes in a large U.S. community oncology cohort," analyzed patients diagnosed with cancer between January 2021 and October 2024, with follow-up through October 2025. Investigators identified 418 patients treated with a GLP-1 receptor agonist and 3,476 non-users, with matching by cancer type and diagnosis year to evaluate overall survival (OS) outcomes.

Key Data Findings

Propensity-score adjusted Cox proportional hazards models evaluated the association between GLP1 RA use and overall survival among patients diagnosed with breast, prostate, colorectal, lung, hepatocellular or renal cancer. After adjustment for confounders including age, BMI, cancer stage and type, GLP‑1 receptor agonist use was significantly associated with improved overall survival (hazard ratio 0.66; 95% CI 0.45–0.97; p = 0.0031).

"While GLP-1 therapies are well established for metabolic disease, emerging preclinical and observational data suggest potential anticancer effects, yet large-scale studies investigating this association have been limited," said Jess Paulus, ScD, vice president of Real-World Research at Ontada and presenting author of the study. "As use of these therapies continues to expand, high-quality real-world data are essential to understanding their broader impact. Our findings demonstrate the value of real-world evidence in identifying anticancer signals and helping efficiently guide future research and prioritization of prospective studies."

Study Methodology

This retrospective analysis used data collected between January 2021 and October 2024, with follow‑up through October 2025, and evaluated GLP‑1 receptor agonist use, including dulaglutide, exenatide, liraglutide, lixisenatide, semaglutide, and tirzepatide. Overall survival was measured from initial cancer diagnosis to death from any cause, with methods applied to address immortal time bias. Among patients who received a GLP‑1 receptor agonist, median age was 63 years, 58% were White, and 57% had a body mass index (BMI) ≥30 kg/m². Semaglutide accounted for the majority of prescriptions (55%). By comparison, non‑users had a median age of 68 years, 58% were White, and 28% had BMI ≥30 kg/m². Most GLP‑1 users (74%) initiated therapy after initial cancer diagnosis, of whom 7% initiated after a metastatic diagnosis, with breast (27%) and prostate (13%) cancers representing the most common malignancies among this group.

"At Ontada, our focus is on advancing cancer care by transforming real-world data into meaningful insights," said Christine Davis, president, Ontada. "This research reflects Ontada’s commitment to generating high-quality, real-world evidence that helps advance how cancer is understood and treated. By studying emerging therapies within community oncology settings, we can help surface insights that inform future research and ultimately support better outcomes for patients."

Other Research & Activities at ASCO (Free ASCO Whitepaper) 2026

Ontada is a part of McKesson, which has a broad portfolio of oncology and multispecialty solutions and partners that provide research, insights, technologies and services that help to address barriers and improve cancer and multispecialty care. At ASCO (Free ASCO Whitepaper), McKesson-supported businesses including The US Oncology Network, Ontada, and Sarah Cannon Research Institute (SCRI), are part of approximately 171 accepted abstracts and presentations. These are inclusive of oral and poster presentations, educational sessions, late-breaking studies and early-phase studies.

For a comprehensive list of Ontada’s 14 accepted abstracts, visit Ontada’s ASCO (Free ASCO Whitepaper) 2026 site. Additionally, visit the Ontada Booth (#30123) at the McCormick Place Convention Center from May 29 – June 2 to explore the data presented at ASCO (Free ASCO Whitepaper) and discuss Ontada’s solutions.

Expert Panel on Community Oncology During ASCO (Free ASCO Whitepaper) 2026

Additionally, McKesson will be participating in a thought leadership panel hosted by Endpoints News on June 3, 2026, at 12 p.m. ET, titled, "Delivering Excellence, Close to Home." Panelists include Jason Hammonds, president of Oncology & Multispecialty for McKesson, John Schuler MD, medical director and radiation oncologist with Compass Oncology, and Dr. Patt. Register and join the panelists as they share their insights and perspectives on what is working today—and what needs to evolve—to support and strengthen community oncology as a foundational component of the cancer care ecosystem.

(Press release, McKesson, MAY 28, 2026, View Source [SID1234666171])